URMC / Research / Clinical Trials / Study Details ILYM17064 / RSRB70432 / Paul BarrResearch Question:What is the safety and efficacy of a new investigational combination of drugs venetoclax in combination with Ublituximab and Umbralisib (TGR-1202)) that have not been tried before?Basic Study Information Purpose:Phase I/II Study of Venetoclax in Combination with Ublituximab and Umbralisib (TGR-1202) in Subjects with Relapsed or Refractory CLL/SLL, Richter's Transformation and Mantle Cell Lymphoma Location: Cancer CenterStudy Web URL: https://clinicaltrials.gov/ct2/show/NCT03379051?term=venetoclax+in+combination+with+Ublituximab&rank=1Study Reference #: ILYM17064Lead Researcher (Principal Investigator) Lead Researcher: Paul Barr Study Contact InformationStudy Coordinator: Amber JohnsonEmail: amber_johnson@urmc.rochester.edu Additional Study Details Learn More About These Conditions More information about Lymphoid leukemia, chronic URMC / Wilmot Cancer Institute /Research / Clinical Trials / Study Details Trial Not Found The study you are looking for is not active at this time. Return to Search